Immunogenicity of anti-tumour necrosis factor therapy in Korean patients with rheumatoid arthritis and ankylosing spondylitis
- 18 April 2014
- journal article
- research article
- Published by Elsevier BV in International Immunopharmacology
- Vol. 21 (1), 20-25
- https://doi.org/10.1016/j.intimp.2014.04.006
Abstract
No abstract availableKeywords
This publication has 25 references indexed in Scilit:
- Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2012: Table 1Annals Of The Rheumatic Diseases, 2013
- Immunogenicity of anti-TNF biologic therapies for rheumatoid arthritisNature Reviews Rheumatology, 2013
- The immunogenicity of anti-TNF therapy in immune-mediated inflammatory diseases: a systematic review of the literature with a meta-analysisAnnals Of The Rheumatic Diseases, 2012
- Adalimumab elicits a restricted anti-idiotypic antibody response in autoimmune patients resulting in functional neutralisationAnnals Of The Rheumatic Diseases, 2012
- Development of Antidrug Antibodies Against Adalimumab and Association With Disease Activity and Treatment Failure During Long-term Follow-upPublished by American Medical Association (AMA) ,2011
- Clinical spectrum of ankylosing spondylitis in KoreaJoint Bone Spine, 2010
- Immunogenicity of Anti-TNF-α Agents in Autoimmune DiseasesClinical Reviews in Allergy & Immunology, 2009
- Imaging and serum analysis of immune complex formation of radiolabelled infliximab and anti-infliximab in responders and non-responders to therapy for rheumatoid arthritisAnnals Of The Rheumatic Diseases, 2006
- Influence of Immunogenicity on the Long-Term Efficacy of Infliximab in Crohn's DiseaseNew England Journal of Medicine, 2003
- Treatment of Rheumatoid Arthritis with a Recombinant Human Tumor Necrosis Factor Receptor (p75)–Fc Fusion ProteinNew England Journal of Medicine, 1997